Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 3/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21287868 | 0.83 | — | — | |
| SCHEMBL16141907 | 0.83 | — | — | |
| SCHEMBL16141906 | 0.78 | DPP4 (0.36) | DPP4SLC6A4SLC6A3 | |
| SCHEMBL8352738 | 0.78 | DPP4 (0.37) | DPP4SLC6A4SLC6A3 | |
| SCHEMBL10190250 | 0.78 | ALDH1A1 (0.44) | DPP4SLC6A4SLC6A3 | |
| SCHEMBL12852762 | 0.78 | ALDH1A1 (0.44) | DPP4SLC6A4SLC6A3 | |
| SCHEMBL12125031 | 0.78 | ESR2 (0.38) | DPP4SLC6A4SLC6A3 | |
| SCHEMBL13167986 | 0.78 | ALDH1A1 (0.44) | DPP4SLC6A4SLC6A3 | |
| SCHEMBL15696443 | 0.78 | ESR2 (0.38) | DPP4SLC6A4SLC6A3 | |
| SCHEMBL17112814 | 0.77 | DPP4 (0.38) | DPP4SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230055321-A1 | PYRIMIDOPYRROLE SPIRO COMPOUNDS AND DERIVATIVES THEREOF AS DNA-PK INHIBITORS | MEDSHINE DISCOVERY INC. (CN) | 2023-02-23 | — | — | US | disclosed |
| EP-3660010-A1 | S1P MODULATING AGENTS | Biogen MA Inc. (US) | 2020-06-03 | — | — | EP | disclosed |
| US-20200038385-A1 | S1P MODULATING AGENTS | BIOGEN IDEC MA INC. | 2020-02-06 | — | — | US | disclosed |
| EP-3150590-B1 | S1P MODULATING AGENTS | BIOGEN MA INC (US) | 2019-10-16 | — | — | EP | disclosed |
| US-10034869-B2 | S1P modulating agents | BIOGEN MA INC. (US) | 2018-07-31 | — | — | US | disclosed |
| EP-2861601-B1 | MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES | GILEAD SCIENCES INC (US) | 2018-02-07 | — | — | EP | disclosed |
| US-20180028511-A1 | S1P MODULATING AGENTS | BIOGEN IDEC MA | 2018-02-01 | — | — | US | disclosed |
| US-9708253-B2 | Cyclohexyl sulfone RORγ modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-07-18 | — | — | US | disclosed |
| US-20170190734-A1 | MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES | Selcia Ltd. (GB) | 2017-07-06 | — | — | US | disclosed |
| US-20170174710-A1 | COMPOUNDS THAT ARE S1P MODULATING AGENTS AND/OR ATX MODULATING AGENTS | BIOGEN MA INC. | 2017-06-22 | — | — | US | disclosed |
| EP-1727812-B1 | NOVEL CYCLOALKYL-CONTAINING 5-ACYLINDOLINONES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICAL PRODUCTS | BOEHRINGER INGELHEIM INT (DE) | 2008-12-31 | — | — | EP | disclosed |
| US-7449447-B2 | Peptidomimetic NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2008-11-11 | — | — | US | disclosed |
| EP-1332133-B1 | METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2008-07-09 | — | — | EP | disclosed |
| US-7309719-B1 | Storage stability; gabapentin and pregabalin, and neutral alpha -amino acid | WARNER LAMBERT COMPANY, LLC (US) | 2007-12-18 | — | — | US | disclosed |
| US-7309719-B1 | Storage stability; gabapentin and pregabalin, and neutral alpha -amino acid | WARNER LAMBERT COMPANY, LLC (US) | 2007-12-18 | — | — | US | disclosed |
| US-20070232549-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION | 2007-10-04 | — | — | US | disclosed |
| WO-2007107565-A1 | BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2007-09-27 | — | — | WO | disclosed |
| US-7244721-B2 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2007-07-17 | — | — | US | disclosed |
| US-20070032433-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION CORVAS INTERNATIONAL, LTD. | 2007-02-08 | — | — | US | disclosed |
| WO-2003082350-A2 | RADIOLABELLED QUINOLINE AND QUINOLINONE DERIVATIVES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR LIGANDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200038385-A1 | S1P MODULATING AGENTS | S1PR2, S1PR1, S1PR3 | DPP4 3341/4885SLC6A4 1994/4885SLC6A3 3379/4885 |
| US-20070232549-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | HPN, TMPRSS15, VIP | DPP4 26/4885SLC6A4 3981/4885SLC6A3 3751/4885 |
| US-20170174710-A1 | COMPOUNDS THAT ARE S1P MODULATING AGENTS AND/OR ATX MODULATING AGENTS | ENPP2, S1PR1, S1PR2 | DPP4 2246/4885SLC6A4 1491/4885SLC6A3 2592/4885 |
| US-10034869-B2 | S1P modulating agents | S1PR2, S1PR1, S1PR3 | DPP4 3133/4885SLC6A4 647/4885SLC6A3 1414/4885 |
| US-20180028511-A1 | S1P MODULATING AGENTS | S1PR2, S1PR1, S1PR3 | DPP4 3341/4885SLC6A4 1994/4885SLC6A3 3379/4885 |
| US-20230055321-A1 | PYRIMIDOPYRROLE SPIRO COMPOUNDS AND DERIVATIVES THEREOF AS DNA-PK INHIBITORS | TYMP, DTYMK, PNKP | DPP4 1192/4885SLC6A4 1264/4885SLC6A3 792/4885 |
| US-20170190734-A1 | MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES | HAVCR2, ZC3HAV1, HCCS | DPP4 238/4885SLC6A4 4237/4885SLC6A3 3828/4885 |
| US-20070032433-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | HPN, TMPRSS15, VIP | DPP4 26/4885SLC6A4 3981/4885SLC6A3 3751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.